Ophthalmic Use: The most frequently reported adverse events in the overall study population were conjunctival irritation, increased lacrimation, keratitis, and papillary conjunctivitis.
These events occurred in approximately 5-10% of patients.Other reported reactions occurring in 1-4% of patients were chemosis, conjunctival hemorrhage, dry eye, eye discharge, eye irritation, eye pain, eyelid edema, headache, red eye, reduced visual acuity and taste disturbance.
NOT FOR INJECTION.ZYMAR® solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.In patients receiving systemic quinolones, including gatifloxacin, serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported.
Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching.
If an allergic reaction to gatifloxacin occurs, discontinue the drug.
Serious acute hypersensitivity reactions may require immediate emergency treatment.Oxygen and airway management should be administered as clinically indicated.